Castle Biosciences Inc (CSTL) Stock Price, Quote & News

Company Profile

Castle Biosciences, Inc., a molecular diagnostics company, provides test solutions for the diagnosis and treatment of dermatologic cancers, Barrett's esophagus (BE), atopic dermatitis (AD), and uveal melanoma. The company offers DecisionDx-Melanoma, a risk stratification gene expression profile (GEP) test that predicts the likelihood of a positive sentinel lymph node and the risk of metastasis for patients with invasive cutaneous melanoma; TissueCypher, a risk stratification spatialomics test to...

Industry: Diagnostics & Research

Sector: Healthcare

Phone: 866 788 9007

Website: castlebiosciences.com

Address:

1500 W. Parkwood Ave, Suite 400, Friendswood, United States

StockNews_Live Mar. 13 at 3:03 PM

$CSTL 🎯 STOCK NEWS ALERT 💵 Price: $25.53 (+0.83%) 🔥 Sentiment Score: 85/100 🚀 VERY POSITIVE NEWS 📄 Castle Biosciences announced the publication of results from the largest prospective, multicenter study to date evaluating DecisionDx-Melanoma’s integrated sentinel lymph node biopsy (i31-SLNB) test… 📎 https://stocknews.live/news/CSTL/prospective-multi-center-study-49232.html

0 · Reply

macroaxis Mar. 11 at 6:36 PM

$CSTL – Volatility Alert: Rising Options Pin Risk Signals Potential Trading Opportunities in Castle Biosciences https://www.macroaxis.com/stock-options/CSTL/Castle-Biosciences?utm_source=dlvr.it&utm_medium=stocktwits

0 · Reply

TheTradeXchange Mar. 9 at 11:01 AM

$CSTL - DecisionDx®-Melanoma’s i31-SLNB: Report from the Largest Prospective Multicenter Study to Date Confirms 2.6% Nodal Positivity in Patients Predicted to Have Less Than 5% Risk

0 · Reply

BillionerOfKing Mar. 2 at 10:25 PM

$CSTL Current Stock Price: $27.98 Contracts to trade: $30.0 CSTL Mar 20 2026 Call Entry: $0.65 Exit: $1.22 ROI: 88% Hold ~28 days Shared as daily free alerts and for educational purposes only. https://dailypickai.com/freealerts

0 · Reply

OfficialStocktwitsUser Feb. 27 at 11:21 PM

$CSTL RSI: 37.66, MACD: -2.1727 Vol: 3.13, MA20: 32.93, MA50: 37.28 🔴 SELL - Downtrend 👉 https://quantumstockalerts.com Disclaimer: I am not a financial advisor. This post reflects personal analysis and opinions only. Please do your own research before investing or trading.

0 · Reply

StocktwitsEarnings Feb. 27 at 7:26 PM

$CSTL Q4 '25 Earnings Results & Recap • Reported GAAP EPS of -$0.08 down -123.53% YoY • Reported revenue of $87.01M up 0.81% YoY • Castle Biosciences anticipates generating between $340M and $350M in total revenue for the full year 2026, reflecting continued growth and market opportunities.

0 · Reply

erevnon Feb. 27 at 1:59 PM

Baird maintains Castle Biosciences $CSTL at Outperform and raises the price target from $41 to https://marketsblock.com/stock-upgrades-and-downgrades/

0 · Reply

StocktwitsEarnings Feb. 26 at 9:17 PM

$CSTL Q4 '25 Earnings Results & Recap • Reported GAAP EPS of -$0.08 down -123.53% YoY • Reported revenue of $87.01M up 0.81% YoY • Castle Biosciences anticipates generating between $340M and $350M in total revenue for 2026. The company expects continued top-line performance and growth of test volumes.

0 · Reply

Dream2121 Feb. 26 at 8:48 PM

$CSTL $40 in 40 minutes.

1 · Reply

OletaPinchback332 Feb. 21 at 6:42 AM

$CSTL Castle Biosciences provides diagnostic testing. Revenue growth depends on clinical adoption. Margins improve with scale.

0 · Reply

Prospective, Multi-center Study Published in Future Oncology Demonstrates DecisionDx®-Melanoma's i31-SLNB Result Outperforms Staging Criteria in Identifying Patients with Cutaneous Melanoma Below the 5% NCCN Threshold for Forgoing SLNB

Mar 9, 2026, 7:00 AM EDT - 7 days ago

DecisionDx®-Melanoma's i31-SLNB: Report from the Largest Prospective Multicenter Study to Date Confirms 2.6% Nodal Positivity in Patients Predicted to Have Less Than 5% Risk

Mar 4, 2026, 4:30 PM EST - 11 days ago

Castle Biosciences to Present Data at SSO 2026 on DecisionDx®-Melanoma's i31-SLNB, Identifying T1b–T2a Melanoma Patients Who May Safely Avoid SLNB

Mar 3, 2026, 4:30 PM EST - 12 days ago

Castle Biosciences Announces Grand Opening of New Corporate Headquarters in Friendswood, Texas

Feb 26, 2026, 8:57 PM EST - 17 days ago

Castle Biosciences, Inc. (CSTL) Q4 2025 Earnings Call Transcript

Feb 26, 2026, 4:05 PM EST - 17 days ago

Castle Biosciences Reports Fourth Quarter and Full–Year 2025 Results

Feb 19, 2026, 5:46 PM EST - 24 days ago

Prospective Validation Study in JAAD Demonstrates Castle Biosciences' AdvanceAD-Tx™ Test Identifies Patients More Likely to Achieve Faster and Deeper Responses with JAK Inhibitor Therapy in Moderate-to-Severe Atopic Dermatitis

Feb 5, 2026, 7:00 AM EST - 5 weeks ago

Castle Biosciences to Release Fourth Quarter and Full-Year 2025 Financial Results and Host Conference Call on Thursday, Feb. 26, 2026

Feb 4, 2026, 2:24 PM EST - 5 weeks ago

Allspring Emerging Growth Fund Q4 2025 Performance Review

AMSC ATI CORT CRS CVLT CWAN TARS

Feb 4, 2026, 8:35 AM EST - 5 weeks ago

Wasatch Micro Cap Fund Q4 2025 Performance Review

AXGN BLZE CLMB MAMA VITL

Jan 11, 2026, 4:00 PM EST - 2 months ago

Castle Biosciences Announces Preliminary Unaudited Fourth Quarter and Full–Year 2025 Results

Dec 19, 2025, 7:00 AM EST - 3 months ago

Castle Biosciences Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Dec 17, 2025, 7:00 AM EST - 3 months ago

Landmark Study Shows Combination of Castle Biosciences' DecisionDx®-UM and PRAME Outperforms Gene Mutation Analysis in Predicting Survival Outcomes in Uveal Melanoma

Dec 12, 2025, 7:00 AM EST - 3 months ago

Systematic Review and Meta-Analysis Confirms TissueCypher® Outperforms Traditional Pathology or Clinical Factors Alone to Identify Patients at Increased Risk of Developing Esophageal Cancer

Dec 9, 2025, 7:00 AM EST - 3 months ago

Expert Melanoma Panel Recommends Castle Biosciences' DecisionDx®-Melanoma as a Best-Practice Tool for Managing Patients with Melanoma

Nov 17, 2025, 7:00 AM EST - 4 months ago

Castle Biosciences Earns a Houston Chronicle Top Workplaces Award for the Fifth Consecutive Year

Nov 14, 2025, 7:00 AM EST - 4 months ago

New Data Confirms Performance of DecisionDx®-Melanoma to Identify Patients with Less Than Five Percent Risk of Sentinel Lymph Node Positivity

Nov 11, 2025, 7:00 AM EST - 4 months ago

Castle Biosciences to Present at the Piper Sandler 37th Annual Healthcare Conference

Nov 5, 2025, 8:02 AM EST - 4 months ago

Why Castle Biosciences' Rally Might Just Be Getting Started

Nov 3, 2025, 11:06 PM EST - 4 months ago

Castle Biosciences, Inc. (CSTL) Q3 2025 Earnings Call Transcript

Nov 3, 2025, 4:07 PM EST - 4 months ago

Castle Biosciences Reports Third Quarter 2025 Results

Nov 3, 2025, 4:05 PM EST - 4 months ago

Castle Biosciences Launches AdvanceAD-Tx™ to Help Guide Systemic Treatment Decision Making in Patients with Moderate-to-Severe Atopic Dermatitis

Oct 28, 2025, 7:00 AM EDT - 4 months ago

Castle Biosciences to Participate in Upcoming Investor Conferences

Oct 26, 2025, 3:05 PM EDT - 5 months ago

New Data at American College of Gastroenterology Annual Meeting Show TissueCypher® Provides Actionable Risk Insights that Influence Clinical Management and Prompt Risk-Aligned Intervention in Barrett's Esophagus

Oct 24, 2025, 4:05 AM EDT - 5 months ago

New Analysis of 13,560 Patients Demonstrates DecisionDx®-Melanoma Stratifies Risk Across Histological Subtypes; Findings to be Presented at Fall Clinical Dermatology Conference

Oct 13, 2025, 7:00 AM EDT - 5 months ago

Castle Biosciences to Release Third Quarter 2025 Financial Results and Host Conference Call on Monday, Nov. 3, 2025

Oct 1, 2025, 4:30 PM EDT - 5 months ago

Castle Biosciences' Founder, President and CEO Derek Maetzold Honored with the CEO of the Year Award by The CEO Magazine

Sep 23, 2025, 7:00 AM EDT - 6 months ago

Castle Biosciences Honored with a Greater Pittsburgh Top Workplaces 2025 Award

Sep 17, 2025, 7:00 AM EDT - 6 months ago

Castle Biosciences Named One of Newsweek's America's Greatest Companies 2025

Sep 9, 2025, 7:00 AM EDT - 6 months ago

New Data at American Foregut Society's 2025 Annual Meeting Demonstrates TissueCypher® Can Detect High-Risk Barrett's Esophagus Patients Not Identified by Pathology to Support Improved Care Decisions

Sep 2, 2025, 9:14 AM EDT - 6 months ago

Castle Biosciences: Strong Margins, Solid Balance Sheet, And Big Upside Potential

Aug 25, 2025, 7:00 AM EDT - 7 months ago

New Evidence Published Supporting Use of DecisionDx®-SCC Test in Guiding and Improving Treatment Pathway Decisions in NCCN High-Risk Cutaneous Squamous Cell Carcinoma

Aug 4, 2025, 10:21 PM EDT - 7 months ago

Castle Biosciences, Inc. (CSTL) Q2 2025 Earnings Call Transcript

Aug 4, 2025, 4:05 PM EDT - 7 months ago

Castle Biosciences Reports Second Quarter 2025 Results

Jul 29, 2025, 7:00 AM EDT - 8 months ago

Castle Biosciences to Present at the Canaccord Genuity 45th Annual Growth Conference

Jul 25, 2025, 7:00 AM EDT - 8 months ago

Castle Biosciences' Founder, President and CEO Derek Maetzold Named a Most Admired CEO by the Houston Business Journal

Jul 23, 2025, 7:00 AM EDT - 8 months ago

FDA Grants Breakthrough Device Designation to Castle Biosciences' DecisionDx®-Melanoma Test

Jul 17, 2025, 7:00 AM EDT - 8 months ago

Castle Biosciences Honored with Multiple Top Workplaces Awards Recognizing the Company's Strong Culture

Jul 14, 2025, 7:00 AM EDT - 8 months ago

Castle Biosciences to Release Second Quarter 2025 Financial Results and Host Conference Call on Monday, Aug. 4, 2025

Jun 16, 2025, 4:30 PM EDT - 9 months ago

Castle Biosciences Enters Collaboration and License Agreement with SciBase to Develop Diagnostic Tests for Dermatologic Diseases

Jun 11, 2025, 7:00 AM EDT - 9 months ago

Castle Biosciences' Chief Executive Officer Derek Maetzold to Participate in Panel Discussion During the 2025 BIO International Convention

Jun 4, 2025, 7:00 AM EDT - 10 months ago

Castle Biosciences' Founder, President and CEO Derek Maetzold Honored with Prestigious Lifetime Achievement Award by The American Business Awards®

May 29, 2025, 4:30 PM EDT - 10 months ago

New Data at ASCO 2025 Affirms DecisionDx®-Melanoma's Ability to Improve Upon Staging-Based Risk Stratification and Predict Survival Outcomes

May 21, 2025, 7:00 AM EDT - 10 months ago

Castle Biosciences to Present at the 2025 Jefferies Global Healthcare Conference

May 9, 2025, 7:00 AM EDT - 11 months ago

Real-World Study Confirms Long-Term Performance of DecisionDx®-UM for Metastatic Risk Stratification in Uveal Melanoma and Utility of PRAME Biomarker for Refining Risk When Considered with the DecisionDx-UM Class Result

May 7, 2025, 7:00 AM EDT - 11 months ago

Castle Biosciences Celebrates Skin Cancer Awareness Month

May 5, 2025, 10:58 PM EDT - 11 months ago

Castle Biosciences, Inc. (CSTL) Q1 2025 Earnings Call Transcript

May 5, 2025, 4:06 PM EDT - 11 months ago

Castle Biosciences Reports First Quarter 2025 Results

May 5, 2025, 4:05 PM EDT - 11 months ago

Castle Biosciences to Acquire Previse

May 2, 2025, 4:30 PM EDT - 11 months ago

New Data at DDW 2025 Further Demonstrates the TissueCypher® Test's Ability to Identify Patients at Increased Risk for Developing Esophageal Cancer

StockNews_Live Mar. 13 at 3:03 PM

0 · Reply

macroaxis Mar. 11 at 6:36 PM

0 · Reply

TheTradeXchange Mar. 9 at 11:01 AM

$CSTL - DecisionDx®-Melanoma’s i31-SLNB: Report from the Largest Prospective Multicenter Study to Date Confirms 2.6% Nodal Positivity in Patients Predicted to Have Less Than 5% Risk

0 · Reply

BillionerOfKing Mar. 2 at 10:25 PM

0 · Reply

OfficialStocktwitsUser Feb. 27 at 11:21 PM

0 · Reply

StocktwitsEarnings Feb. 27 at 7:26 PM

0 · Reply

erevnon Feb. 27 at 1:59 PM

Baird maintains Castle Biosciences $CSTL at Outperform and raises the price target from $41 to https://marketsblock.com/stock-upgrades-and-downgrades/

0 · Reply

StocktwitsEarnings Feb. 26 at 9:17 PM

$CSTL Q4 '25 Earnings Results & Recap • Reported GAAP EPS of -$0.08 down -123.53% YoY • Reported revenue of $87.01M up 0.81% YoY • Castle Biosciences anticipates generating between $340M and $350M in total revenue for 2026. The company expects continued top-line performance and growth of test volumes.

0 · Reply

Dream2121 Feb. 26 at 8:48 PM

$CSTL $40 in 40 minutes.

1 · Reply

OletaPinchback332 Feb. 21 at 6:42 AM

$CSTL Castle Biosciences provides diagnostic testing. Revenue growth depends on clinical adoption. Margins improve with scale.

0 · Reply

Flibenson Feb. 19 at 2:56 PM

$CSTL https://www.prnewswire.com/news-releases/merlin-cp-gep-becomes-the-first-and-only-gene-expression-profile-gep-test-recommended-by-nccn-cutaneous-melanoma-guidelines-to-assess-metastatic-risk-302692470.html

0 · Reply

Flibenson Feb. 19 at 2:47 PM

0 · Reply

ZacksResearch Feb. 18 at 2:49 PM

$NVO's Wegovy gets EC nod for higher dose — but is it enough to boost the stock? NVO shares down 9.9% in six months, lagging the industry’s 27.4% growth New 7.2 mg Wegovy dose shows promising weight loss results, yet the stock carries a Zacks Rank #5 (Strong Sell) Some better-ranked stocks are $HRMY, $ALKS, and $CSTL. Opportunity or risk? Full analysis here 👉 https://www.zacks.com/stock/news/2871232/eu-approves-novo-nordisks-higher-dose-wegovy-for-obesity-patients?cid=sm-stocktwits-2-2871232-body-33960&ADID=SYND_STOCKTWITS_TWEET_2_2871232_BODY_33960

0 · Reply

DonaldLefort773 Feb. 18 at 12:36 PM

$CSTL Diagnostics platform benefiting from preventative healthcare adoption; reimbursement stability is critical.

0 · Reply

commoncentsinvestor Feb. 6 at 5:53 PM

$CSTL ABEO selling for $5 with almost $4 in cash, new FDA approved Zevaskyn now on market. Going to fly.

0 · Reply

CapitalPilot Feb. 4 at 2:25 PM

$CSTL is a clinical-stage biotech developing cell therapies for cancer; it is a high-risk, early-stage company in the competitive cell therapy space.

1 · Reply

OfficialStocktwitsUser Jan. 28 at 8:58 PM

$CSTL RSI: 44.49, MACD: 0.8802 Vol: 1.31, MA20: 40.41, MA50: 39.19 🟢 BUY - Uptrend + healthy RSI 👉 https://quantumstockalerts.com Disclaimer: I am not a financial advisor. This post reflects personal analysis and opinions only. Please do your own research before investing or trading.

0 · Reply

BioTechNoir Jan. 26 at 3:23 PM

$CSTL new 52 week

0 · Reply

SuperGreenToday Jan. 23 at 7:36 PM

$CSTL Share Price: $41.69 Contract Selected: Jul 17, 2026 $40 Calls Buy Zone: $5.10 – $6.30 Target Zone: $9.57 – $11.69 Potential Upside: 77% ROI Time to Expiration: 174 Days | Updates via https://fxcapta.com/stockinfo/

0 · Reply

BioTechNoir Jan. 22 at 3:27 PM

$CSTL new 52 week

0 · Reply

StockConsultant Jan. 16 at 6:11 PM

$CSTL Castle Biosciences stock, watch for a narrow range breakout at https://stockconsultant.com/?CSTL

0 · Reply

wiseman88 Jan. 13 at 2:41 PM

$CSTL preliminary reports show another strong quarter and finish to 2025. Expecting a good bump here until Feb earnings call.

0 · Reply

Market Cap	759.92M
Revenue (ttm)	344.23M
Net Income (ttm)	-24.16M
EPS (ttm)	N/A
PE Ratio	0.00
Forward PE	N/A
Profit Margin	-7.02%
Debt to Equity Ratio	0.02

Volume	245,400
Avg Vol	425,092
Day's Range	N/A - N/A
Shares Out	29.73M
Stochastic %K	18%
Beta	1.09
Analysts	Strong Sell
Price Target	$48.50